MDM2 and cancer: It is well documented that targeting the p53 pathway in TP53 MT cancer is ineffective and represents a persistent barrier to existing MDM2/MDMX-p53 targeted therapeutics due to their inability to exploit MDM2/MDMX’s p53-independent mechanisms.